Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04400500
Other study ID # 01-02/20
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 1, 2020
Est. completion date November 30, 2023

Study information

Verified date December 2023
Source National Medical Research Center for Therapy and Preventive Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To evaluate possibilities of rapid differential diagnosis and risk stratification in patients urgently admitted to the CCU with a suspected acute coronary syndrome without persistent ST-segment elevation (NSTEACS).


Description:

Single centre prospective non-randomised non-comparative study of patients delivered by ambulance and admitted to the CCU with suspected NSTEACS. Aims of this study are: 1. To characterize the contingent of patients admitted to the CCU with suspected NSTEACS. 2. To evaluate possibilities of fast differential diagnosis and risk stratification in patients admitted to the CCU with suspected NSTEACS using clinical data, ECG, biomarker levels (hsTn, NT-proBNP, hsCPR, cardiac FABP) as well as HEART, ADAPT, EDACS, T-MACS, GRACE, ACTION and TIMI scores. 3. To evaluate the correlation between clinical data, ECG, biomarker levels (hsTn, NT-proBNP, hsCPR, cardiac FABP) as well as HEART, ADAPT, EDACS, T-MACS, GRACE, ACTION and TIMI scores with presence and severity of coronary atherosclerosis in patients admitted to the CCU (intensive care unit) with suspected NSTEACS.


Recruitment information / eligibility

Status Completed
Enrollment 140
Est. completion date November 30, 2023
Est. primary completion date November 30, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Delivered by ambulance to the CCU with suspected diagnosis "acute coronary syndrome (ACS)". 2. Signed informed consent. Exclusion Criteria: 1. ACS with persistent ST-segment elevation. 2. Moribund; extremely severe condition on admission with a potentially unfavourable prognosis (cardiogenic shock, coma, cardiac arrest, an urgent need for mechanical ventilation). 3. Overt non-cardiac cause of clinical manifestations at the time of admission (bleeding, pulmonary embolism, aortic dissection, stroke).

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Approaches to differential diagnosis and risk stratification
Detailed analysis of clinical course, ECG, biomarkers (hsTn I, CK-MB mass, myoglobin, NT-proBNP, hsCPR, cardiac FABP on admission and after 3 hours; hsTn I, CK-MB mass and myoglobin after 6 hours if needed) as well as HEART, ADAPT, EDACS, T-MACS, GRACE, ACTION and TIMI scores.

Locations

Country Name City State
Russian Federation Eramishantsev Hospital Moscow

Sponsors (1)

Lead Sponsor Collaborator
National Research Center for Preventive Medicine

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Other Urgent revascularisation Revascularisation performed due to sudden clinical deterioration Up to 1 monts
Other Other adverse events All adverse events/complications not included in clinical outcomes end points. 6 months.
Primary Clinical outcomes Composite of death, (re) infarction, stroke or re-hospitalization 6 monts
Primary Final diagnosis Final diagnosis - the main reason for urgent hospitalization - according to hospital case history Up to 1 monts
Secondary Death Death upon discharge and up to 6 months 6 months.
Secondary (re) infarction (re) infarction upon discharge and up to 6 months Up to 1 monts
Secondary Stroke Stroke upon discharge and up to 6 months 6 months.
Secondary Re-hospitalization Recurrent hospital admissions after discharge form the index hospitalization 6 months.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Recruiting NCT05117866 - Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study N/A
Recruiting NCT02578537 - COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS Phase 4
Recruiting NCT06051110 - Individual Patient Data Meta-analysis on Prehospital Risk Assessment in Patients Suspected of Non-ST-segment Elevation Acute Coronary Syndrome N/A
Withdrawn NCT03300167 - Study of the Vascular Response to Percutaneous Coronary Intervention in Patients With Non-ST-elevation Acute Coronary Syndromes Using Intravascular Blood Sampling N/A
Terminated NCT02071966 - Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS Phase 4
Not yet recruiting NCT06096909 - Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population N/A
Recruiting NCT05125276 - Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients Phase 4
Recruiting NCT03863327 - EKG Criteria and Identification of Acute Coronary Occlusion
Completed NCT01962428 - Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI Phase 4
Recruiting NCT04476173 - ANalgesic Efficacy and Safety of MOrphiNe Versus Methoxyflurane in Patients With Acute Myocardial Infarction Phase 3
Recruiting NCT06255678 - Angio-based Final Functional Effect of PCI
Not yet recruiting NCT06197724 - MCG for Identification of Myocardial Ischemia in Suspected NSTE-ACS Patients
Recruiting NCT05250596 - COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS) Phase 2
Completed NCT02073565 - HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt N/A
Completed NCT04766437 - Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy Phase 2
Not yet recruiting NCT05202041 - Non-IRA Functional Evaluation With AccuFFRangio in NSTE-ACS N/A
Recruiting NCT02415803 - Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS Phase 3
Not yet recruiting NCT05779059 - Prasugrel Or Ticagrelor De-escalation in NSTE-ACS Phase 3